Hong Kong Retail Distributors Stock News

SEHK:2268
SEHK:2268Life Sciences

Assessing WuXi XDC Cayman (SEHK:2268) Valuation After New Earendil Labs ADC Licensing Deal

WuXi XDC Cayman (SEHK:2268) just expanded its ADC platform reach as Earendil Labs secured an exclusive global license to the WuXiTecan-2 payload-linker technology, structured with upfront, milestone and royalty economics. See our latest analysis for WuXi XDC Cayman. The Earendil Labs agreement, which highlights WuXi XDC Cayman’s ADC and payload platform, comes as the shares trade at HK$63.15, with a 1 day share price return of 8.23%, a 30 day share price return of 2.02%, and a 1 year total...
SEHK:83
SEHK:83Real Estate

Sino Land (SEHK:83) Margin Compression Tests Bullish Earnings Growth Narrative Ahead Of H1 2026

Intro Sino Land (SEHK:83) has opened H1 2026 earnings season with a set of numbers that put revenue and EPS firmly in focus, as investors weigh how the latest figures square with expectations for a business priced at HK$12.78 per share. The company has seen half year revenue move from HK$3,842 million in H2 2024 to HK$3,854 million in H1 2025 and HK$4,329 million in H2 2025, while basic EPS over those periods came in at HK$0.2082, HK$0.209 and HK$0.243 respectively. This gives a clear line of...
SEHK:868
SEHK:868Building

Xinyi Glass Holdings (SEHK:868) Margin Compression Challenges Bullish Growth Narratives

Xinyi Glass Holdings (SEHK:868) has put fresh numbers on the table for FY 2025, with first half revenue of C¥9.8b and basic EPS of C¥0.23, setting the tone for how the rest of the year might shape up. The company has seen revenue move from C¥10.9b in the first half of 2024 to C¥9.8b in the latest half, while EPS has shifted from C¥0.59 to C¥0.23. These shifts sit against trailing twelve month EPS of C¥0.62 on revenue of C¥20.8b. With trailing net margin at 13.1% versus 15.1% a year earlier,...
SEHK:1523
SEHK:1523Communications

Plover Bay Technologies (SEHK:1523) Net Margin Expansion Tests Bullish Growth Narratives

Plover Bay Technologies (SEHK:1523) has opened FY 2025 with first half revenue of US$62.9 million and basic EPS of US$0.019649, setting a clear marker for how the year is shaping up. The company has seen revenue move from US$57.3 million in the first half of 2024 to US$59.5 million in the second half and then to US$62.9 million in the first half of 2025. Basic EPS has tracked from US$0.017356 to US$0.0172 and then to US$0.019649 over the same periods, giving investors a clear view of the top...
SEHK:2696
SEHK:2696Biotechs

Shanghai Henlius Biotech (SEHK:2696) Valuation Check After Strong 1 Year Total Shareholder Return

Shanghai Henlius Biotech (SEHK:2696) has caught investor attention after a strong 1 year total return of 144%, alongside revenue of CN¥5,797.88 and net income of CN¥824.30, prompting closer scrutiny of its valuation. See our latest analysis for Shanghai Henlius Biotech. Despite a recent 7 day share price return of 7.2% decline and some short term volatility, Shanghai Henlius Biotech’s 1 year total shareholder return of 144.26% and very large 3 year total shareholder return suggest momentum...
SEHK:1361
SEHK:1361Luxury

Assessing 361 Degrees International (SEHK:1361) Valuation After Robust Multi‑Year Shareholder Returns

361 Degrees International (SEHK:1361) has drawn fresh attention after recent share price moves, prompting investors to reassess how its current valuation lines up with its reported earnings, revenue profile, and longer term return record. See our latest analysis for 361 Degrees International. The latest move to HK$5.65 caps a steady year to date share price return of 5.02%, while the 1 year total shareholder return of 47% and 5 year total shareholder return of 194.4% point to strong longer...
SEHK:1211
SEHK:1211Auto

Assessing BYD (SEHK:1211) Valuation After Recent Share Price Weakness

Context for BYD’s recent share performance BYD (SEHK:1211) has drawn investor attention after a period where the share price showed a 7.6% decline over the past month and a 2.6% decline over the past 3 months. See our latest analysis for BYD. Looking beyond the recent 7.6% one month share price decline, BYD’s 1 year total shareholder return of 22.5% decline contrasts with a 30.47% gain over three years and 50.87% over five years. This suggests that longer term momentum has cooled. If this...
SEHK:1810
SEHK:1810Tech

Xiaomi Supreme Court Royalty Case And What It Means For Valuation

Xiaomi has taken its tariff and royalty dispute to India's Supreme Court, challenging a tribunal ruling on how certain payments tied to imports should be taxed. The case centers on whether royalty payments linked to technology and brand use should be added to the customs value of imported components. The outcome could shape future tax treatment for contract manufacturing arrangements used by Xiaomi and other multinational producers in India. Xiaomi, traded as SEHK:1810, is contesting this...
SEHK:340
SEHK:340Metals and Mining

Assessing Tongguan Gold Group (SEHK:340) Valuation After Strong 2025 Profit Guidance Draws Investor Attention

Tongguan Gold Group (SEHK:340) drew fresh attention after issuing 2025 earnings guidance, projecting profit attributable to owners of HK$820 million to HK$840 million, including about HK$55 million of non operating derivative related expenses. See our latest analysis for Tongguan Gold Group. The strong 2025 earnings guidance has arrived after a period of intense momentum, with a 90 day share price return of 39.15% and a very large 1 year total shareholder return. The latest 1 day move of...
SEHK:6990
SEHK:6990Biotechs

A Look At Sichuan Kelun-Biotech Biopharmaceutical’s Valuation After The Crescent Biopharma Oncology Partnership

Why the Crescent Biopharma partnership matters for Sichuan Kelun-Biotech Biopharmaceutical The new collaboration between Crescent Biopharma and Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) on next generation oncology drugs, including joint clinical trials, is drawing fresh attention from investors to Kelun-Biotech's pipeline and funding position. See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical. At the latest share price of HK$387.4, Sichuan Kelun-Biotech...
SEHK:100
SEHK:100Software

Assessing MiniMax Group (SEHK:100) Valuation After A Sharp Month Long Share Price Rally

MiniMax Group stock moves after sharp month-long rally MiniMax Group (SEHK:100) has drawn fresh attention after a sharp move in its share price over the past month, prompting investors to reassess the newly listed AI foundation model developer. See our latest analysis for MiniMax Group. The latest pullback, including a 3.17% 1 day share price return decline and 21.29% 7 day share price return decline, comes after a 56.45% 30 day and 121.30% year to date share price return. This suggests...
SEHK:6855
SEHK:6855Biotechs

Assessing Ascentage Pharma Group International (SEHK:6855) Valuation After Recent Share Price Volatility

Recent share move and business snapshot Ascentage Pharma Group International (SEHK:6855) has seen its share price move recently, with a 1 day return of about 1.4% and a decline of roughly 26.9% over the past 3 months, drawing attention to its clinical stage biotech profile. See our latest analysis for Ascentage Pharma Group International. Looking beyond the latest move, the share price has recorded a 4.9% decline over the past month and a 26.9% decline over the past quarter, while the 1 year...
SEHK:866
SEHK:866Oil and Gas

A Look At China Qinfa Group (SEHK:866) Valuation After Guidance For A 2025 Loss

China Qinfa Group (SEHK:866) has issued new earnings guidance, telling investors to expect a loss after taxation of not more than CN¥98,000,000 for 2025, compared with a profit of about CN¥556,370,000 in 2024. See our latest analysis for China Qinfa Group. The earnings guidance sits against a very strong recent run in the stock, with a 1-day share price return of 8.09% and a year to date share price return of 41.67%. The 1-year total shareholder return is very large and multi year total...
SEHK:1093
SEHK:1093Pharmaceuticals

CSPC Pharmaceutical Group (SEHK:1093) Valuation Check After New Long-Acting Obesity And Pain Drug Trial Approvals

CSPC Pharmaceutical Group (SEHK:1093) has received regulatory clearance for two long-acting drug candidates, including a monthly GLP-1/GIP injection in the US and a week-long ropivacaine pain therapy trial in China. See our latest analysis for CSPC Pharmaceutical Group. These trial approvals arrive after a strong 116.18% 1-year total shareholder return and a 25.16% 90-day share price return, although the 30-day share price return of 6.16% and recent 7-day weakness suggest shorter term...
SEHK:293
SEHK:293Airlines

A Look At Cathay Pacific Airways (SEHK:293) Valuation After JPMorgan’s Upgrade

JPMorgan’s upgrade of Cathay Pacific Airways (SEHK:293), which followed the expiry of its buyback plan on 24 February 2026, has put fresh attention on the airline’s balance sheet, cash generation, and sizeable aircraft commitments. See our latest analysis for Cathay Pacific Airways. At a share price of HK$14.06, Cathay Pacific’s recent 7 day share price return of 10.53% and 90 day share price return of 16.58% sit alongside a 1 year total shareholder return of 46.56%. This suggests momentum...
SEHK:512
SEHK:512Pharmaceuticals

Assessing Grand Pharmaceutical Group (SEHK:512) Valuation After Recent Earnings And Share Price Pressure

Grand Pharmaceutical Group (SEHK:512) has drawn investor attention after posting annual revenue of HK$11,704.979 million and net income of HK$2,079.449 million, putting fresh focus on how its diversified healthcare business is currently valued. See our latest analysis for Grand Pharmaceutical Group. At a share price of HK$7.83, Grand Pharmaceutical Group has seen short term share price pressure, with a 90 day share price return decline of 4.74%. However, its 1 year total shareholder return of...
SEHK:968
SEHK:968Semiconductor

A Look At Xinyi Solar Holdings (SEHK:968) Valuation After Weaker Full Year 2025 Results

Full year 2025 results and what changed Xinyi Solar Holdings (SEHK:968) has released full year 2025 results showing sales of CNY 20,861.16 million and net income of CNY 844.53 million, both lower than the previous year. This is likely shaping current investor sentiment. See our latest analysis for Xinyi Solar Holdings. The share price has reacted to the weaker full year 2025 results, but still shows a 13.07% year to date share price return and a 7.45% 90 day share price return. However, the 3...
SEHK:992
SEHK:992Tech

Lenovo Group (SEHK:992) Is Up 5.5% After New AI-Driven Server Support And Edge Launches

Earlier this week, Lenovo announced Premier Support Plus for Servers, its highest-tier, AI-driven enterprise support for ThinkSystem and ThinkAgile servers, and expanded its ThinkEdge portfolio with new rugged, AI-ready edge computing devices, including the SE10n Gen 2, SE30n Gen 2, SE60n Gen 2, and the SE50a Panel PC. Taken together, these launches highlight Lenovo’s push to pair AI-enabled infrastructure with premium, proactive support services aimed at always-on, mission-critical...
SEHK:656
SEHK:656Industrials

Could Fosun International’s ESG Reporting Award Reframe Its Long-Term Credibility Story (SEHK:656)?

On 23 February 2026, Fosun International received the "Certificate of Excellence in Environmental, Social and Governance Reporting" from the Hong Kong Management Association, recognizing its ESG reporting quality and climate-related disclosure efforts. This award underlines how Fosun’s “Create IMPACT” sustainable development strategy has embedded transparency, climate action, and governance into its core business approach. We’ll now examine how Fosun’s strengthened ESG reporting and climate...
SEHK:2
SEHK:2Electric Utilities

CLP Holdings (SEHK:2) Margin Slippage Challenges Earnings Resilience Narrative

CLP Holdings (SEHK:2) has just posted its FY 2025 first half numbers, with revenue of HK$42.9b and basic EPS of HK$2.23, setting the tone for how its earnings story is evolving. The company has seen revenue move from HK$44.1b in 1H 2024 to HK$46.9b in 2H 2024 and HK$42.9b in 1H 2025, while EPS has gone from HK$2.36 to HK$2.29 and then HK$2.23 over the same periods. This puts the focus squarely on how margins are holding up through the latest results. See our full analysis for CLP...
SEHK:175
SEHK:175Auto

Is It Time To Reconsider Geely (SEHK:175) After Recent Hong Kong Auto Sector Sentiment Shift?

If you are wondering whether Geely Automobile Holdings is attractively priced or not, this article will walk you through what the current share price might be implying about its value. The stock last closed at HK$16.31, with a 7 day return of 4.3% decline, a 30 day return of 1.3% decline, a year to date return of 10.4% decline, a 1 year return of 12.4% decline and a 3 year return of 66.1% alongside a 5 year return of 27.7% decline. This gives a mixed picture for investors weighing recent...
SEHK:2689
SEHK:2689Forestry

Nine Dragons Paper H1 Profit Margin Rebound Tests Bearish Earnings Narratives

Latest Earnings Snapshot Nine Dragons Paper (Holdings) (SEHK:2689) has reported H1 2026 results that keep the recent turnaround in focus, with trailing twelve month revenue at C¥66.997b and basic EPS at C¥0.83 alongside a 252% year-on-year rise in reported earnings and a net profit margin of 4.9% versus 1.5% a year earlier. The company has seen half year revenue move from C¥28.885b in H2 2024 to C¥29.776b in H2 2025. Basic EPS went from C¥0.10 in H1 2025 to C¥0.28 in H2 2025, setting up a...
SEHK:1
SEHK:1Industrials

Assessing CK Hutchison Holdings (SEHK:1) Valuation After A Strong 1 Year Shareholder Return

Why CK Hutchison Holdings Is On Investors’ Radar CK Hutchison Holdings (SEHK:1) has caught investor attention after a strong past 3 months, with a return of about 18%, which is prompting a closer look at how its diversified operations and earnings profile compare. See our latest analysis for CK Hutchison Holdings. At a current share price of HK$64.8, CK Hutchison’s recent 4.52% 1 day share price return and 17.93% 90 day share price return sit alongside a 71.89% 1 year total shareholder...
SEHK:3690
SEHK:3690Hospitality

Meituan (SEHK:3690) Valuation Check As 2025 Loss Guidance Follows A Profitable 2024

What Meituan’s 2025 Loss Guidance Means for Investors Meituan (SEHK:3690) has issued earnings guidance for 2025, flagging an expected loss of about CN¥23.3b to CN¥24.3b, compared with a profit of roughly CN¥35.8b in 2024. The company links this swing to an anticipated operating loss of around CN¥6.8b to CN¥7b in its Core Local Commerce segment and to higher spending on overseas expansion, which it frames as a response to intense industry competition. See our latest analysis for...